Primary source: Open Government Licence v3.0
Enhanced surveillance and trapping activities have been initiated in response to the detection of Aedes aegypti mosquitoes in east London.
The presence of invasive Aedes aegypti, which can transmit diseases like dengue, chikungunya, and Zika virus, prompts the need for increased public health vigilance, despite the risk being assessed as very low.
UKHSA has implemented control measures to destroy larvae and is monitoring the area closely for further mosquito activity.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
UKHSA has implemented control measures to destroy larvae and is monitoring the area closely for further mosquito activity.
The UK Health Security Agency (UKHSA) has detected invasive Aedes aegypti mosquitoes breeding in residential properties in east London, leading to enhanced surveillance and control measures. This is the first occurrence of breeding in the UK, indicating a need for vigilance and potential public health monitoring.
What changed: Enhanced surveillance and trapping activities have been initiated in response to the detection of Aedes aegypti mosquitoes in east London.
Why it matters: The presence of invasive Aedes aegypti, which can transmit diseases like dengue, chikungunya, and Zika virus, prompts the need for increased public health vigilance, despite the risk being assessed as very low.
Practical implication: UKHSA has implemented control measures to destroy larvae and is monitoring the area closely for further mosquito activity.
Published from the regulator source ingestion pipeline after PV impact triage.
Healthcare professionals and consumers are directed to report any adverse events related to the use of ZUBB Dietary Supplement to the FDA's MedWatch Program.
Update product labeling to include new efficacy data and boxed warnings, incorporate the new treatment into compliance protocols, and increase monitoring for adverse events associated with Etcamah.
Healthcare professionals must act on the issued FSNs as outlined by MHRA, ensuring compliance to address any safety concerns associated with the listed medical devices.
Users of affected products must conduct thorough visual inspections of the VentStar circuits prior to use and will receive free replacements for any affected circuits.
